Aug 31 (Reuters) - HLS Therapeutics Inc HLS.TO :
* VASCEPA® (ICOSAPENT ETHYL) REPORTED TO SIGNIFICANTLY REDUCE CORONARY PLAQUE IN EVAPORATE STUDY FINAL RESULTS PRESENTED AT ESC CONGRESS 2020
* HLS THERAPEUTICS INC - PRIMARY ENDPOINT OF SLOWED CORONARY PLAQUE PROGRESSION REPORTED TO HAVE BEEN MET WITH VASCEPA